Joseph Song1, Priyanka Kadaba1, Amanda Kravitz1, Adilia Hormigo2, Joshua Friedman2, Puneet Belani1, Constantinos Hadjipanayis3, Benjamin M Ellingson4, Kambiz Nael4. 1. Icahn School of Medicine at Mount Sinai, Department of Radiology (Neuroimaging Advanced and Exploratory Lab), New York, New York. 2. Department of Neurology, Medicine (Div Hem Onc), The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 3. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York. 4. UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Abstract
BACKGROUND: Physiologic changes quantified by diffusion and perfusion MRI have shown utility in predicting treatment response in glioblastoma (GBM) patients treated with cytotoxic therapies. We aimed to investigate whether quantitative changes in diffusion and perfusion after treatment by immune checkpoint inhibitors (ICIs) would determine 6-month progression-free survival (PFS6) in patients with recurrent GBM. METHODS: Inclusion criteria for this retrospective study were: (i) diagnosis of recurrent GBM treated with ICIs and (ii) availability of diffusion and perfusion in pre and post ICI MRI (iii) at ≥6 months follow-up from treatment. After co-registration, mean values of the relative apparent diffusion coefficient (rADC), Ktrans (volume transfer constant), Ve (extravascular extracellular space volume) and Vp (plasma volume), and relative cerebral blood volume (rCBV) were calculated from a volume-of-interest of the enhancing tumor. Final assignment of stable/improved versus progressive disease was determined on 6-month follow-up using modified Response Assessment in Neuro-Oncology criteria. RESULTS: Out of 19 patients who met inclusion criteria and follow-up (mean ± SD: 7.8 ± 1.4 mo), 12 were determined to have tumor progression, while 7 had treatment response after 6 months of ICI treatment. Only interval change of rADC was suggestive of treatment response. Patients with treatment response (6/7: 86%) had interval increased rADC, while 11/12 (92%) with tumor progression had decreased rADC (P = 0.001). Interval change in rCBV, Ktrans, Vp, and Ve were not indicative of treatment response within 6 months. CONCLUSIONS: In patients with recurrent GBM, interval change in rADC is promising in assessing treatment response versus progression within the first 6 months following ICI treatment. KEY POINTS: • In recurrent GBM treated with ICIs, interval change in rADC suggests early treatment response.• Interval change in rADC can be used as an imaging biomarker to determine PFS6.• Interval change in MR perfusion and permeability measures do not suggest ICI treatment response.
BACKGROUND: Physiologic changes quantified by diffusion and perfusion MRI have shown utility in predicting treatment response in glioblastoma (GBM) patients treated with cytotoxic therapies. We aimed to investigate whether quantitative changes in diffusion and perfusion after treatment by immune checkpoint inhibitors (ICIs) would determine 6-month progression-free survival (PFS6) in patients with recurrent GBM. METHODS: Inclusion criteria for this retrospective study were: (i) diagnosis of recurrent GBM treated with ICIs and (ii) availability of diffusion and perfusion in pre and post ICI MRI (iii) at ≥6 months follow-up from treatment. After co-registration, mean values of the relative apparent diffusion coefficient (rADC), Ktrans (volume transfer constant), Ve (extravascular extracellular space volume) and Vp (plasma volume), and relative cerebral blood volume (rCBV) were calculated from a volume-of-interest of the enhancing tumor. Final assignment of stable/improved versus progressive disease was determined on 6-month follow-up using modified Response Assessment in Neuro-Oncology criteria. RESULTS: Out of 19 patients who met inclusion criteria and follow-up (mean ± SD: 7.8 ± 1.4 mo), 12 were determined to have tumor progression, while 7 had treatment response after 6 months of ICI treatment. Only interval change of rADC was suggestive of treatment response. Patients with treatment response (6/7: 86%) had interval increased rADC, while 11/12 (92%) with tumor progression had decreased rADC (P = 0.001). Interval change in rCBV, Ktrans, Vp, and Ve were not indicative of treatment response within 6 months. CONCLUSIONS: In patients with recurrent GBM, interval change in rADC is promising in assessing treatment response versus progression within the first 6 months following ICI treatment. KEY POINTS: • In recurrent GBM treated with ICIs, interval change in rADC suggests early treatment response.• Interval change in rADC can be used as an imaging biomarker to determine PFS6.• Interval change in MR perfusion and permeability measures do not suggest ICI treatment response.
Authors: Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin Journal: Neuro Oncol Date: 2014-01-15 Impact factor: 12.300
Authors: F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jeffrey S Weber; Adil Daud; Omid Hamid; Amita Patnaik; Antoni Ribas; Caroline Robert; Tara C Gangadhar; Anthony M Joshua; Peter Hersey; Roxana Dronca; Richard Joseph; Darcy Hille; Dahai Xue; Xiaoyun Nicole Li; S Peter Kang; Scot Ebbinghaus; Andrea Perrone; Jedd D Wolchok Journal: J Clin Oncol Date: 2016-03-07 Impact factor: 44.544
Authors: Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados Journal: Neuro Oncol Date: 2008-03-04 Impact factor: 12.300
Authors: Eric Bouffet; Valérie Larouche; Brittany B Campbell; Daniele Merico; Richard de Borja; Melyssa Aronson; Carol Durno; Joerg Krueger; Vanja Cabric; Vijay Ramaswamy; Nataliya Zhukova; Gary Mason; Roula Farah; Samina Afzal; Michal Yalon; Gideon Rechavi; Vanan Magimairajan; Michael F Walsh; Shlomi Constantini; Rina Dvir; Ronit Elhasid; Alyssa Reddy; Michael Osborn; Michael Sullivan; Jordan Hansford; Andrew Dodgshun; Nancy Klauber-Demore; Lindsay Peterson; Sunil Patel; Scott Lindhorst; Jeffrey Atkinson; Zane Cohen; Rachel Laframboise; Peter Dirks; Michael Taylor; David Malkin; Steffen Albrecht; Roy W R Dudley; Nada Jabado; Cynthia E Hawkins; Adam Shlien; Uri Tabori Journal: J Clin Oncol Date: 2016-03-21 Impact factor: 44.544
Authors: Anna Sophie Berghoff; Barbara Kiesel; Georg Widhalm; Orsolya Rajky; Gerda Ricken; Adelheid Wöhrer; Karin Dieckmann; Martin Filipits; Anita Brandstetter; Michael Weller; Sebastian Kurscheid; Monika E Hegi; Christoph C Zielinski; Christine Marosi; Johannes A Hainfellner; Matthias Preusser; Wolfgang Wick Journal: Neuro Oncol Date: 2014-10-29 Impact factor: 12.300
Authors: Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins Journal: Nat Med Date: 2019-02-11 Impact factor: 53.440
Authors: Akifumi Hagiwara; Talia C Oughourlian; Nicholas S Cho; Jacob Schlossman; Chencai Wang; Jingwen Yao; Catalina Raymond; Richard Everson; Kunal Patel; Sergey Mareninov; Fausto J Rodriguez; Noriko Salamon; Whitney B Pope; Phioanh L Nghiemphu; Linda M Liau; Robert M Prins; Timothy F Cloughesy; Benjamin M Ellingson Journal: Neuro Oncol Date: 2022-06-01 Impact factor: 13.029
Authors: Otto M Henriksen; María Del Mar Álvarez-Torres; Patricia Figueiredo; Gilbert Hangel; Vera C Keil; Ruben E Nechifor; Frank Riemer; Kathleen M Schmainda; Esther A H Warnert; Evita C Wiegers; Thomas C Booth Journal: Front Oncol Date: 2022-03-03 Impact factor: 5.738
Authors: Christine E Brown; Samantha Bucktrout; Lisa H Butterfield; Olga Futer; Evanthia Galanis; Adilia Hormigo; Michael Lim; Hideho Okada; Robert Prins; Sara Siebel Marr; Kirk Tanner Journal: J Transl Med Date: 2022-05-23 Impact factor: 8.440
Authors: Yan Li; Yiqi Ma; Zijun Wu; Ruoxi Xie; Fanxin Zeng; Huawei Cai; Su Lui; Bin Song; Lei Chen; Min Wu Journal: Front Immunol Date: 2021-11-25 Impact factor: 7.561
Authors: Ming Zhu; Sijia Li; Yu Kuang; Virginia B Hill; Amy B Heimberger; Lijie Zhai; Shengjie Zhai Journal: Front Oncol Date: 2022-08-02 Impact factor: 5.738
Authors: Nicholas S Cho; Akifumi Hagiwara; Blaine S C Eldred; Catalina Raymond; Chencai Wang; Francesco Sanvito; Albert Lai; Phioanh Nghiemphu; Noriko Salamon; Lori Steelman; Islam Hassan; Timothy F Cloughesy; Benjamin M Ellingson Journal: Neurooncol Adv Date: 2022-08-04